지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2013.1
- 수록면
- 95 - 102 (8page)
이용수
초록· 키워드
오류제보하기
Purpose A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced nonsquamous NSCLC.
Materials and Methods Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR)mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone,pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain.
Results The median age of the cohort was 65 years (range, 31 to 88 years) . The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%)patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006),whole-body metastatic score (p<0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS.
Conclusion The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
Norihisa Y / 2008 / Stereotactic body radiotherapy for oligometastatic lung tumors / Int J Radiat Oncol Biol Phys 72:398~403
Takeda A / 2011 / Stereotactic body radiotherapy (SBRT) for oligome-tastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer / Radiother Oncol 101:255~259
Welsh JS / 2002 / Helical tomotherapy: an innovative technology and approach to radiation therapy / Technol Cancer Res Treat 1:311~316
Aggarwal C / 2012 / Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer / Curr Opin Oncol 24 :
Arrieta O / 2011 / Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemora
Takeda A / 2011 / Stereotactic body radiotherapy (SBRT) for oligome-tastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer / Radiother Oncol 101:255~259
Welsh JS / 2002 / Helical tomotherapy: an innovative technology and approach to radiation therapy / Technol Cancer Res Treat 1:311~316
Aggarwal C / 2012 / Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer / Curr Opin Oncol 24 :
Arrieta O / 2011 / Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemora
이 논문의 저자 정보
최근 본 자료
댓글(0)
0